Fidelity Management & Research, a multinational financial services corporation, led a $100m in Agomab Therapeutics, a Belgian biotech company, with participation from EQT Life Sciences, Canaan and Dawn Biopharma. “With the addition of these world-class investors we continue to build the company as a leader in the field of fibrosis and have secured the funding required to conduct clinical studies for multiple drug candidates. I am very pleased to be able to work with the new board to further develop our potentially game-changing therapeutics for the many patients in high need for anti-fibrotic therapies,” Tim Knotnerus, Agomab Therapeutics CEO.